公开(公告)号：EP2089024B1

公开(公告)日：2011-05-18

申请号：EP07868853.8

申请日：2007-11-27

申请人： Novartis AG ,  Dana-Farber Cancer Institute, Inc.

发明人： GRIFFIN, James Douglas ,  ZAWEL, Leigh

IPC分类号： A61K31/427 ,  A61K31/437 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/553 ,  A61K31/427 ,  A61K31/437 ,  A61K31/704 ,  A61K31/7068 ,  A61K2300/00

公开(公告)号：EP2089024A2

公开(公告)日：2009-08-19

申请号：EP07868853.8

申请日：2007-11-27

申请人： NOVARTIS AG ,  Dana-Farber Cancer Institute, Inc.

发明人： GRIFFIN, James Douglas ,  ZAWEL, Leigh

IPC分类号： A61K31/427 ,  A61K31/437 ,  A61K31/553 ,  A61K31/704 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/553 ,  A61K31/427 ,  A61K31/437 ,  A61K31/704 ,  A61K31/7068 ,  A61K2300/00

摘要： The present invention relates to combinations of IAP inhibitors and FLT3 inhibitors, pharmacological compositions comprising said combination, methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the second mitochondria-derived activator of caspase (Smac) protein to inhibitor of apoptosis (IAPs) (IAP inhibitor) and one or more pharmaceutically active agents and the use of these combinations for the treatment of acute myeloid leukemia; and a commercial package comprising said combination.

公开(公告)号：EP3515559A1

公开(公告)日：2019-07-31

申请号：EP17853809.6

申请日：2017-09-20

申请人： Dana-Farber Cancer Institute, Inc. ,  Buhrlage, Sara ,  Weisberg, Ellen ,  Griffin, James Douglas

发明人： BUHRLAGE, Sara ,  WEISBERG, Ellen ,  GRIFFIN, James Douglas

IPC分类号： A61P35/02 ,  C07K16/30 ,  C12N5/09